Kirsty

Insulin aspart, the active ingredient in Kirsty, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in adults and children requiring insulin therapy.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics, temperature‑controlled shipping, and comprehensive documentation for import clearance.

Insulin aspart is a rapid‑acting insulin analog used to manage blood glucose levels in diabetes mellitus.

Type 1 diabetes mellitus: provides mealtime insulin coverage to reduce post‑prandial hyperglycaemia. Type 2 diabetes mellitus: added when oral agents are insufficient to achieve target HbA1c, offering rapid glucose control. Diabetic ketoacidosis (DKA) emergency management: used intravenously to quickly lower plasma glucose while correcting metabolic acidosis. Gestational diabetes mellitus: may be prescribed under specialist supervision to control post‑prandial spikes. Insulin pump therapy: serves as a rapid‑acting bolus insulin for continuous subcutaneous insulin infusion devices.

Insulin aspart may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose levels causing shakiness, sweating, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue at injection sites. - Nausea: mild stomach discomfort or queasiness. - Headache: transient head pain.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: life‑threatening allergic response with rash, swelling, or breathing difficulty. - Angioedema: swelling of face, lips, or tongue. - Lipohypertrophy: large fatty deposits causing erratic insulin absorption. - Edema: peripheral swelling due to fluid retention. - Hypokalemia: low potassium levels, especially with high insulin doses.

When using insulin aspart, several precautions should be observed to ensure safety and efficacy. - Dose titration: adjust dose based on self‑monitored blood glucose and carbohydrate intake. - Hypoglycemia risk: monitor closely for signs of low blood sugar, especially after meals or exercise. - Renal impairment: reduce dose in patients with reduced kidney function to avoid accumulation. - Cardiovascular disease: use cautiously in patients with heart failure or coronary artery disease. - Pregnancy and lactation: consider benefits versus risks; use only if clearly needed under medical supervision. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the product.

Insulin aspart can interact with other medicines, altering its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid): - Beta‑blockers: mask hypoglycemia symptoms and prolong insulin action. - Sulfonylureas: additive glucose‑lowering effect may cause severe hypoglycemia. - Alcohol: potentiates insulin’s hypoglycemic action, especially with binge drinking.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Thiazolidinediones: increase insulin resistance reversal, heightening hypoglycemia risk. - Diuretics: may affect electrolyte balance, influencing insulin activity. - Thyroid hormones: alter metabolic rate, potentially modifying insulin requirements.